Rahib Lola, Salerno William, Abu-El-Haija Maisam, Conwell Darwin L, Freeman A Jay, Hart Phil A, Pandol Stephen J, Perito Emily R, Yadav Dhiraj, Palermo Tonya M
Mission: Cure, New York, New York, USA.
Division of Gastroenterology, Hepatology and Nutrition Cincinnati Children's Hospital Medical Center, Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA.
Pancreatology. 2024 Dec;24(8):1237-1243. doi: 10.1016/j.pan.2024.11.013. Epub 2024 Nov 19.
BACKGROUND/OBJECTIVE: Recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) lack effective therapies. There is no consensus or guidance on which endpoints or outcome measures should be used in clinical trials. This study aimed to develop a core outcome set aligned with both patient and provider priorities for RAP and CP. Utilizing the Outcomes Measures in Rheumatology (OMERACT) framework, a multi-stakeholder approach was adopted to identify and prioritize outcome domains.
A two-round Delphi poll was conducted among four stakeholder groups: adult patients, parents and pediatric patients, adult health care providers and pediatric health care providers. Steering committee consensus further refined the core outcome domains, categorizing them as mandatory, important but optional, or research agenda domains, with full consensus achieved.
Pain severity, ability to participate in social roles and activities, pancreatitis related hospitalization/ER visits and acute pancreatitis flare-ups were recommended as mandatory outcome domains for future clinical trials in RAP/CP.
Using the OMERACT framework, we developed a core outcome set for RAP and CP. Future research will focus on identifying validated measures for each domain, facilitating standardized assessments across clinical trials.
背景/目的:复发性急性胰腺炎(RAP)和慢性胰腺炎(CP)缺乏有效的治疗方法。对于临床试验应使用哪些终点指标或结局测量方法,目前尚无共识或指导意见。本研究旨在制定一套与RAP和CP患者及医疗服务提供者优先事项相一致的核心结局集。利用风湿病学结局测量(OMERACT)框架,采用多利益相关方方法来确定结局领域并对其进行优先级排序。
在四个利益相关方群体中进行了两轮德尔菲调查:成年患者、家长和儿科患者、成年医疗服务提供者和儿科医疗服务提供者。指导委员会达成的共识进一步完善了核心结局领域,将其分为强制性、重要但非必需或研究议程领域,并达成了完全共识。
疼痛严重程度、参与社会角色和活动的能力、胰腺炎相关住院/急诊就诊以及急性胰腺炎发作被推荐作为未来RAP/CP临床试验的强制性结局领域。
使用OMERACT框架,我们制定了RAP和CP的核心结局集。未来的研究将集中于为每个领域确定经过验证的测量方法,以促进临床试验中的标准化评估。